Viewing Study NCT06987734


Ignite Creation Date: 2025-12-25 @ 2:29 AM
Ignite Modification Date: 2025-12-31 @ 10:50 AM
Study NCT ID: NCT06987734
Status: RECRUITING
Last Update Posted: 2025-06-26
First Post: 2025-05-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Cancer (NSCLC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Neoadjuvant View
None NSCLC View
None immunotherapy View
None adjuvant View